Sam Chun Dang Pharm. Co., Ltd

KOSDAQ:A000250 Stock Report

Market Cap: ₩3.6t

Sam Chun Dang Pharm Dividends and Buybacks

Dividend criteria checks 0/6

Sam Chun Dang Pharm does not currently pay a dividend.

Key information

0%

Dividend yield

-2.0%

Buyback Yield

Total Shareholder Yield-2.0%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per share₩50.000
Payout ratio0%

Recent dividend and buyback updates

No updates

Recent updates

Here's Why Sam Chun Dang Pharm (KOSDAQ:000250) Has A Meaningful Debt Burden

Dec 22
Here's Why Sam Chun Dang Pharm (KOSDAQ:000250) Has A Meaningful Debt Burden

Risks Still Elevated At These Prices As Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Shares Dive 26%

Nov 30
Risks Still Elevated At These Prices As Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Shares Dive 26%

Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Investors Are Less Pessimistic Than Expected

Oct 05
Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Investors Are Less Pessimistic Than Expected

Sam Chun Dang Pharm (KOSDAQ:000250) Takes On Some Risk With Its Use Of Debt

Sep 08
Sam Chun Dang Pharm (KOSDAQ:000250) Takes On Some Risk With Its Use Of Debt

Subdued Growth No Barrier To Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) With Shares Advancing 44%

Jun 19
Subdued Growth No Barrier To Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) With Shares Advancing 44%

Is Sam Chun Dang Pharm (KOSDAQ:000250) A Risky Investment?

Jun 09
Is Sam Chun Dang Pharm (KOSDAQ:000250) A Risky Investment?

Optimistic Investors Push Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Shares Up 28% But Growth Is Lacking

Mar 21
Optimistic Investors Push Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Shares Up 28% But Growth Is Lacking

Sam Chun Dang Pharm (KOSDAQ:000250) Seems To Use Debt Quite Sensibly

Feb 26
Sam Chun Dang Pharm (KOSDAQ:000250) Seems To Use Debt Quite Sensibly

Investors Who Bought Sam Chun Dang Pharm (KOSDAQ:000250) Shares Five Years Ago Are Now Up 644%

Feb 09
Investors Who Bought Sam Chun Dang Pharm (KOSDAQ:000250) Shares Five Years Ago Are Now Up 644%

Could The Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Ownership Structure Tell Us Something Useful?

Jan 05
Could The Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Ownership Structure Tell Us Something Useful?

Here's Why Sam Chun Dang Pharm (KOSDAQ:000250) Can Manage Its Debt Responsibly

Dec 01
Here's Why Sam Chun Dang Pharm (KOSDAQ:000250) Can Manage Its Debt Responsibly

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if A000250's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A000250's dividend payments have been increasing.


Dividend Yield vs Market

Sam Chun Dang Pharm Dividend Yield vs Market
How does A000250 dividend yield compare to the market?
SegmentDividend Yield
Company (A000250)0%
Market Bottom 25% (KR)1.2%
Market Top 25% (KR)4.0%
Industry Average (Pharmaceuticals)1.1%
Analyst forecast (A000250) (up to 3 years)n/a

Notable Dividend: Unable to evaluate A000250's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A000250's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: A000250 is not paying a notable dividend for the KR market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A000250 has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 22:47
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sam Chun Dang Pharm. Co., Ltd is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyung Soo KimCape Investment & Securities Co., Ltd.
Al Eum LeeiM Securities
Hong-Sik JeongLS Securities Co., Ltd.